These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37054461)

  • 1. Acute visual change as first symptom of B-cell prolymphocytic leukaemia.
    Hawley L; Eaton O; Han L
    N Z Med J; 2023 Apr; 136(1573):114-116. PubMed ID: 37054461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Eyre TA; Fox CP; Shankara P; Went R; Schuh AH
    Br J Haematol; 2017 May; 177(3):486-491. PubMed ID: 27061924
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib.
    George P; Brown A; Weinkove R
    Pathology; 2020 Jun; 52(4):491-492. PubMed ID: 32349864
    [No Abstract]   [Full Text] [Related]  

  • 5. Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
    Patil N; Went RG
    Br J Haematol; 2019 Aug; 186(4):e80-e82. PubMed ID: 30941750
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.
    Chen LY; Eyre TA
    Eur J Haematol; 2022 Nov; 109(5):590-592. PubMed ID: 35871485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mononeuritis multiplex in a patient with B-cell prolymphocytic leukaemia: a diagnostic challenge.
    Le Clech L; Rizcallah MJ; Alavi Z; Hutin P
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24000206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CD5-positive B-cell prolymphocytic leukemia].
    Inoue T; Yoshida M; Oowashi K; Yoshida T
    Rinsho Ketsueki; 2010 Jan; 51(1):80-2. PubMed ID: 20134145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-prolymphocytic leukemia: Is it time to retire this entity?
    El Hussein S; Khoury JD; Medeiros LJ
    Ann Diagn Pathol; 2021 Oct; 54():151790. PubMed ID: 34293709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo B-cell prolymphocytic leukemia with central nervous system involvement.
    Tatarczuch M; Blombery P; Seymour JF
    Leuk Lymphoma; 2014 Jul; 55(7):1665-7. PubMed ID: 24047478
    [No Abstract]   [Full Text] [Related]  

  • 11. Relapsed B-cell prolymphocytic leukemia (B-PLL) with distinctive granular inclusion bodies.
    Su MY; Chen TC; Teng CJ; Wu CH
    Int J Lab Hematol; 2024 Aug; 46(4):585-586. PubMed ID: 38284307
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical characteristics of 8 patients with B-cell prolymphocytic leukemia].
    Zhang YR; Li ZJ; Yu Z; Yi SH; Feng XY; Zou DH; Qi JY; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):544-5. PubMed ID: 23827118
    [No Abstract]   [Full Text] [Related]  

  • 13. An unusual cause of delirium and debility: refractory hypercalcemia in a man with B-cell prolymphocytic leukemia.
    Loh KP; Dahiya S; Brennan MJ
    J Am Geriatr Soc; 2014 Oct; 62(10):2021-2. PubMed ID: 25333559
    [No Abstract]   [Full Text] [Related]  

  • 14. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia].
    Nakashima H; Saito B; Ariizumi H; Matsuda I; Nakamaki T; Tomoyasu S
    Rinsho Ketsueki; 2008 Dec; 49(12):1619-22. PubMed ID: 19110524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
    Telek B; Batár P; Rejto L; Udvardy M
    Orv Hetil; 2010 Aug; 151(31):1261-3. PubMed ID: 20656663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax.
    Christoforidou A; Bezirgiannidou Z; Vrachiolias G; Papoutselis M; Spanoudakis E; Kotsianidis Ι
    Leuk Lymphoma; 2020 Mar; 61(3):749-752. PubMed ID: 31713446
    [No Abstract]   [Full Text] [Related]  

  • 18. Auer Rod-Like Inclusions in B-Cell Prolymphocytic Leukemia.
    Zhao Y; Lv J
    Turk J Haematol; 2019 Nov; 36(4):280-281. PubMed ID: 30238921
    [No Abstract]   [Full Text] [Related]  

  • 19. A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
    Tempescul A; Feuerbach J; Ianotto JC; Dalbies F; Marion V; Le Bris MJ; De Braekeleer M; Berthou C
    Ann Hematol; 2009 Jan; 88(1):85-8. PubMed ID: 18654781
    [No Abstract]   [Full Text] [Related]  

  • 20. T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging!
    Sellner L
    Acta Haematol; 2021; 144(1):4-5. PubMed ID: 32392564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.